Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3856)
All Articles published online
|
Apr 28, 2011 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen YY, Yeh CN, Cheng CT, Chen TW, Rau KM, Jan YY, Chen MF. Sunitinib for Taiwanese patients with gastrointestinal stromal tumor after imatinib treatment failure or intolerance. World J Gastroenterol 2011; 17(16): 2113-2119 [PMID: 21547131 DOI: 10.3748/wjg.v17.i16.2113] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v17/i16/2113.htm |
| Number | Citing Articles |
| 1 |
Hiromitsu Kitayama, Michiaki Hirayama, Junko Sugiyama, Tomohiro Kondo, Yumiko Oyamada, Sho Takahashi, Yasushi Tsuji. Complete response of gastrointestinal stromal tumor liver metastases to regorafenib. International Cancer Conference Journal 2015; 4(3): 167 doi: 10.1007/s13691-014-0192-4
|
| 2 |
Yanli Nie, Wenjia Sun, Zhihua Xiao, Shengwei Ye. Complete response to sunitinib for more than three years in a patient with a jejunum gastrointestinal stromal tumor. Medicine 2019; 98(3): e14060 doi: 10.1097/MD.0000000000014060
|
| 3 |
Jun-Te Hsu, Puo-Hsien Le, Chang-Fu Kuo, Meng-Jiun Chiou, Chia-Jung Kuo, Tsung-Hsing Chen, Chun-Jung Lin, Jen-Shi Chen, Huang-Pin Yu, Chun-Nan Yeh, Yi-Yin Jan, Ta-Sen Yeh. Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study. Oncotarget 2017; 8(41): 71128 doi: 10.18632/oncotarget.16795
|
| 4 |
Chia‑Hsiang Hu, Chun‑Nan Yeh, Jen‑Shi Chen, Chun‑Yi Tsai, Shang‑Yu Wang, Chi‑Tung Cheng, Ta‑Sen Yeh. Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non‑randomized, single‑center study. Oncology Letters 2020; 20(3): 2131 doi: 10.3892/ol.2020.11756
|
| 5 |
Chun-Nan Yeh, Tsann-Long Hwang, Ching-Shui Huang, Po-Huang Lee, Chew-Wun Wu, Ker Chen-Guo, Yi-Yin Jan, Miin-Fu Chen. Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan. World Journal of Surgical Oncology 2012; 10(1) doi: 10.1186/1477-7819-10-246
|
| 6 |
L. M. Kogonia, A. M. Koroleva. Second line of therapy for gastrointestinal stromal tumors: is there a choice?. Medical Council 2019; (10): 28 doi: 10.21518/2079-701X-2019-10-28-36
|
| 7 |
Weili Yang, Kai Li, Jiren Yu, Chunhui Shou, Qing Zhang, Yanyun Hong, Jianyi Sun, Hang Yu, Yuan Gao, Qianyun Shen, Zhicheng Zhao, Shusen Zheng. Clinical outcomes of imatinib dose escalation versus sunitinib in first-line imatinib-failure gastrointestinal stromal tumour. Scandinavian Journal of Gastroenterology 2018; 53(10-11): 1328 doi: 10.1080/00365521.2018.1518484
|
| 8 |
Chun-Nan Yeh, Wen-Hung Chung, Shih-Chi Su, Yen-Yang Chen, Chi-Tung Cheng, Yen-Ling Lin, Wan-Chun Chang, Rosaline Chung-Yee Hui, Kun-Chun Chiang, Tsung-Wen Chen, Yi-Yin Jan, Chien-Wei Chen, Ting-Jui Chen, Chih-Hsun Yang, Shuen-Iu Hung. Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib-Induced Hand-Foot Skin Reaction. Journal of Investigative Dermatology 2014; 134(11): 2768 doi: 10.1038/jid.2014.218
|
| 9 |
Atul B. Shinagare, Constance M. Barysauskas, Marta Braschi-Amirfarzan, Ailbhe C. O'Neill, Paul J. Catalano, Suzanne George, Nikhil H. Ramaiya. Comparison of performance of various tumor response criteria in assessment of sunitinib activity in advanced gastrointestinal stromal tumors. Clinical Imaging 2016; 40(5): 880 doi: 10.1016/j.clinimag.2016.04.007
|
| 10 |
Chiao-En Wu, Chiao-Ping Chen, Wen-Kuan Huang, Yi-Ru Pan, Erhan Aptullahoglu, Chun-Nan Yeh, John Lunec. p53 as a biomarker and potential target in gastrointestinal stromal tumors. Frontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.872202
|
| 11 |
Siyuan Tan, Ping Chen, Jiafu Ji, Shanshan Guo, Dapeng Yu, Tetsuya Asakawa, Yu Zhou, Masanobu Abe, Liang Zong. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review. Disease Markers 2018; 2018: 1 doi: 10.1155/2018/1368617
|
| 12 |
Haruyuki Takaki, Tess Litchman, Ann Covey, Franois Cornelis, Majid Maybody, George I. Getrajdman, Constantinos T. Sofocleous, Karen T. Brown, Stephen B. Solomon, William Alago, Joseph P. Erinjeri. Hepatic Artery Embolization for Liver Metastasis of Gastrointestinal Stromal Tumor Following Imatinib and Sunitinib Therapy. Journal of Gastrointestinal Cancer 2014; 45(4): 494 doi: 10.1007/s12029-014-9663-2
|
| 13 |
Chun-Nan Yeh, Ming-Huang Chen, Yen-Yang Chen, Ching-Yao Yang, Chueh-Chuan Yen, Chin-Yuan Tzen, Li-Tzong Chen, Jen-Shi Chen. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17. Oncotarget 2017; 8(27): 44121 doi: 10.18632/oncotarget.17310
|
| 14 |
Rodrigo Panno Basilio-de-Oliveira, Vera Lucia Nunes Pannain. Prognostic angiogenic markers (endoglin, VEGF, CD31) and tumor cell proliferation (Ki67) for gastrointestinal stromal tumors. World Journal of Gastroenterology 2015; 21(22): 6924-6930 doi: 10.3748/wjg.v21.i22.6924
|
| 15 |
Tsuyoshi Shirakawa, Tomoya Hirata, Kosuke Maemura, Toshiyuki Goto, Yoshiya Shimao, Kosuke Marutsuka, Yuji Ueda, Ikuo Kikuchi. Complete response to second-line chemotherapy with sunitinib of a gastrointestinal stromal tumor: A case report. Molecular and Clinical Oncology 2017; 7(1): 93 doi: 10.3892/mco.2017.1268
|
| 16 |
Fuming Xie, Weidong Xiao, Yahui Jiang, Xiao Xia, Yaxu Wang. Relationship between efficacy of sunitinib and KIT mutation of patients with advanced gastrointestinal stromal tumors after failure of imatinib. Medicine 2019; 98(19): e15478 doi: 10.1097/MD.0000000000015478
|
| 17 |
Chun-Nan Yeh, Yen-Yang Chen, Jeng-Hwei Tseng, Jen-Shi Chen, Tsung-Wen Chen, Chun-Yi Tsai, Chi-Tung Cheng, Yi-Yin Jan, Miin-Fu Chen. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Translational Oncology 2011; 4(6): 328 doi: 10.1593/tlo.11253
|
| 18 |
UMUT KEFELI, MUSTAFA BENEKLI, ALPER SEVINC, RAMAZAN YILDIZ, MUHAMMED ALI KAPLAN, AYDIN CILTAS, OZAN BALAKAN, ABDURRAHMAN ISIKDOGAN, UGUR COSKUN, FAYSAL DANE, HAKAN HARPUTLUOGLU, HALIT KARACA, DOGAN YAZILITAS, AYSE DURNALI, ALI OSMAN KAYA, UMUT DEMIRCI, MAHMUT GUMUS, SULEYMAN BUYUKBERBER. Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience. Oncology Letters 2013; 6(2): 605 doi: 10.3892/ol.2013.1408
|
| 19 |
Samantha C. Sodergren, Alice White, Fabio Efficace, Mirjam Sprangers, Deborah Fitzsimmons, Andrew Bottomley, Colin D. Johnson. Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Critical Reviews in Oncology/Hematology 2014; 91(1): 35 doi: 10.1016/j.critrevonc.2014.01.002
|
| 20 |
Chiao-En Wu, Chin-Yuan Tzen, Shang-Yu Wang, Chun-Nan Yeh. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers 2019; 11(5): 679 doi: 10.3390/cancers11050679
|
| 21 |
YAN LIU, HE-LONG ZHANG, YE ZHANG, JIA-ZHUAN MEI, HONG-WEI LIN, YAN-WEI GUO, RUI-JUN LI, XIANG-RUI MENG, GUI-JU LIU, MIN LI, PENG XIAO, HUA BAI. Digestive tract hemorrhage due to complications with gastrointestinal stromal tumor treated with sunitinib: A case report. Oncology Letters 2013; 5(2): 699 doi: 10.3892/ol.2012.1050
|
| 22 |
Hamad Ghaleb Dailah, Abdullah Abdu Hommdi, Mahdi Dafer Koriri, Essa Mohammed Algathlan, Syam Mohan. Potential role of immunotherapy and targeted therapy in the treatment of cancer: A contemporary nursing practice. Heliyon 2024; 10(2): e24559 doi: 10.1016/j.heliyon.2024.e24559
|